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Abstract 
 
Chlamydia trachomatis is a bacterial pathogen that is the leading cause of bacterial “Sexual 
Transmitted Disease” (STD) in developing countries. Most often the infection is asymptomatic. 
However, if the infection remains untreated, it often results in pelvic inflammatory disease (PID), 
ectopic pregnancy, chronic pelvic pain in women, urethritis and epididymitis in men or infant 
pneumonia. The infection can easily be treated with antibiotics, but in most cases damage is 
already done before the bacterium is noticed. Immunization is considered to be the best approach 
to reduce C. trachomatis infections. However, so far no vaccine is available.  
In this study, plasmid DNA (pWRG7079::MOMP) expressing the major outer membrane protein 
of a human Chlamydia trachomatis serovar E strain was tested for the ability to induce an 
immune response and protect against experimental genital infection with the same serovar. The 
vaccine was tested in pigs, as they are genetically, physiologically and immunologically related 
to humans and suitable for studying C. trachomatis infection of the genital system. To increase 
the immune response, GM-CSF and LTa+LTb were used as adjuvants. GM-CSF was 
administered seven days before immunization, while the other adjuvants were administered 
together with the vaccine. Ten pigs were randomly divided into two groups. One group received 
an intravaginal primo-vaccination and a booster of 500 µg pWRG7079::MOMP, while the other 
group received the placebo vaccine pWRG7079. All animals were challenged intravaginally with 
108 TCID50
 
 of C. trachomatis serovar E. Pigs immunized with the DNA vaccine showed 
significantly less macroscopic lesions, vaginal excretion and chlamydial replication in the genital 
tract, as compared to placebo-vaccinated controls. A clear relationship could be detected between 
high stimulation indices in the lymphocyte proliferation assays and better protection. However, 
the infection could not be completely cleared.  
 
